An interventional study of axitinib and crizotinib in Solid Tumors, sponsored by Pfizer. Completed at 34 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Pfizer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
This is a roll over study aimed to provide continued access to axitinib (monotherapy or combination, according to treatment received in prior axitinib study) to patients who have documented stable, or responding disease, or received clinical benefit (as defined by protocol) at the time of the prior study closure.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
Drug: axitinib · Drug: crizotinib
BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
Also known as: AG-013736
BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
Also known as: PF-02341066
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and non-serious AEs.
Time frame: Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow-up to approximately 120.56 months)
A total of 52 participants were enrolled in this study, out of which 49 were treated. Enrollment for this study was planned to be conducted into two groups: Axitinib monotherapy and Axitinib combination therapy. However, no participant enrolled in Axitinib combination therapy group.
| Milestone | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other |
|---|---|---|---|---|---|
| Started | 7 | 9 | 20 | 2 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 9 | 20 | 2 | 11 |
| Withdrew: Death | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 2 | 1 | 3 |
| Withdrew: Objective progression or relapse | 4 | 4 | 11 | 0 | 5 |
| Withdrew: No longer willing to participate in study | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Insufficient clinical response | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Subject refused continued treatment for reason other than adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and non-serious AEs.
| Participants | Overall | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other |
|---|---|---|---|---|---|---|
| TEAEs | 49 | 7 | 9 | 20 | 2 | 11 |
| Serious TEAEs | 21 | 4 | 8 | 5 | 0 | 4 |
| Treatment Related TEAEs | 47 | 7 | 9 | 18 | 2 | 11 |
| Treatment Related Serious TEAEs | 15 | 2 | 7 | 3 | 0 | 3 |
Collected over Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow up to approximately 120.56 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | 5/49 (10.2%) | 21/49 (42.9%) | 48/49 (98%) |
| Axitinib 2 mg | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Axitinib 3 mg | 1/9 (11.1%) | 8/9 (88.9%) | 9/9 (100%) |
| Axitinib 5 mg | 3/20 (15%) | 5/20 (25%) | 19/20 (95%) |
| Axitinib 7 mg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Other | 0/11 (0%) | 4/11 (36.4%) | 11/11 (100%) |
| Event | Overall | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other |
|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 6/49 | 0/7 | 5/9 | 0/20 | 0/2 | 1/11 |
| Acute coronary syndromeCardiac disorders | 2/49 | 0/7 | 2/9 | 0/20 | 0/2 | 0/11 |
| VomitingGastrointestinal disorders | 2/49 | 0/7 | 2/9 | 0/20 | 0/2 | 0/11 |
| DehydrationMetabolism and nutrition disorders | 3/49 | 0/7 | 2/9 | 1/20 | 0/2 | 0/11 |
| NeutropeniaBlood and lymphatic system disorders | 1/49 | 1/7 | 0/9 | 0/20 | 0/2 | 0/11 |
| Acute myocardial infarctionCardiac disorders | 3/49 | 1/7 | 1/9 | 1/20 | 0/2 | 0/11 |
| EnterocolitisGastrointestinal disorders | 1/49 | 1/7 | 0/9 | 0/20 | 0/2 | 0/11 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/49 | 1/7 | 0/9 | 0/20 | 0/2 | 0/11 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/49 | 1/7 | 0/9 | 0/20 | 0/2 | 0/11 |
| DizzinessNervous system disorders | 1/49 | 1/7 | 0/9 | 0/20 | 0/2 | 0/11 |
| Event | Overall | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 30/49 | 3/7 | 9/9 | 10/20 | 2/2 | 6/11 |
| NauseaGastrointestinal disorders | 11/49 | 1/7 | 3/9 | 2/20 | 2/2 | 3/11 |
| FatigueGeneral disorders | 21/49 | 1/7 | 6/9 | 6/20 | 2/2 | 6/11 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 9/49 | 2/7 | 0/9 | 3/20 | 2/2 | 2/11 |
| HypertensionVascular disorders | 28/49 | 3/7 | 7/9 | 11/20 | 2/2 | 5/11 |
| ProteinuriaRenal and urinary disorders | 14/49 | 5/7 | 1/9 | 5/20 | 0/2 | 3/11 |
| Weight decreasedInvestigations | 17/49 | 1/7 | 5/9 | 7/20 | 1/2 | 3/11 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 19/49 | 1/7 | 5/9 | 7/20 | 1/2 | 5/11 |
| HypothyroidismEndocrine disorders | 16/49 | 3/7 | 4/9 | 5/20 | 1/2 | 3/11 |
| ConstipationGastrointestinal disorders | 6/49 | 0/7 | 2/9 | 1/20 | 1/2 | 2/11 |
Safety population included all participants who received at least one dose of axitinib under A4061008 protocol.
| Age, Continuous(Years) | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other | Total |
|---|---|---|---|---|---|---|
| Mean | 61.6 ± 14.7 | 57.1 ± 11.3 | 58.5 ± 4.2 | 68.5 ± 3.5 | 64.6 ± 8.6 | 60.4 ± 9.0 |
| Sex: Female, Male(Participants) | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 2 | 4 | 1 | 5 | 14 |
| Male | 5 | 7 | 16 | 1 | 6 | 35 |
| Race (NIH/OMB)(Participants) | Axitinib 2 mg | Axitinib 3 mg | Axitinib 5 mg | Axitinib 7 mg | Other | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 2 | 4 | 0 | 0 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 2 | 5 | 14 | 2 | 9 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 0 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Mar 2003 to primary completion in Aug 2023, 245 months.
Results were first posted in Dec 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib